Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tobira Therapeutics has received a new patent from the US Patent and Trademark Office that covers the use of TBR-652, a CCR5 antagonist currently in Phase I development for the treatment of HIV-1 infection in adults.
Subscribe to our email newsletter
This patent is part of Tobira’s portfolio of medicines to treat infectious diseases. In addition, the company recently received a European patent for TBR-220, a second CCR5 antagonist for the treatment of HIV/AIDS.
James Sapirstein, CEO of Tobira Therapeutics, said: “It is gratifying to progress the intellectual property of these compounds and look forward to future clinical trial results.”